No blanket recommendation can be made for SGLT2 inhibitors and GLP-1 receptor agonists in adults with type 2 diabetes (T2D) without considering cardiovascular and kidney risks, according to a BMJ ...

Adults with type 2 diabetes who initiate SGLT2 inhibitors within 3 months of a diagnosis of a urinary tract infection have a ...

Canagliflozin is generally well tolerated and improves blood sugar control in children and adolescents with type 2 diabetes, ...

Germany: A retrospective cohort study has found that prior use of SGLT2 inhibitors in type 2 diabetes mellitus (T2DM) ...

Children and adolescents with type 2 diabetes had greater reductions in HbA1c with an oral SGLT2 inhibitor compared with ...

SGLT2 inhibitors were associated with a lower risk for major adverse cardiovascular events and heart failure hospitalization compared with DPP-4 inhibitors among patients with type 2 diabetes ...

SGLT2 harvests sodium and glucose from the waste moving through the nephrons, and returns them to the blood. Blocking it with the inhibitors reduces blood sugar levels by forcing the sodium and ...

Of note, the researchers projected that first-line SGLT2 inhibitors and GLP-1 receptor agonists would slightly increase overall life expectancy, by 3 and 3.4 months, respectively.

This latest approval builds on an earlier liquid formulation of generic methimazole for feline hyperthyroidism, which ...

Sodium glucose co-transporter-2 (SGLT2) inhibitors do not lead to lower 28-day all-cause mortality compared with usual care or placebo in patients hospitalized with COVID-19, according to late ...

With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online conversations reveals cardiologists are still cautious. AstraZeneca had already been quick to consider ...

There’s no question that SGLT2 inhibitors are coming to make a difference. Neil Minkoff, MD: Let me ask Dr Desai, and I’ll come right back to you, Steve.